Modifications to a type of immune cell programmed to recognize and kill cancerous tumors could make them even more effective ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...

Researchers at MIT and Harvard University found that in the sample with modified 'killer' cells, the cancer did not spread.

AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago ...

The latest update is out from Oncopeptides AB ( (SE:ONCO) ).

Cancer Immunotherapy Could Be Transformed By Boosting Natural Killer Cells. Researchers at MIT and Harvard Medical School have developed a method to enhance natural killer cells that could transform ...

Stockholm – November 3, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that a collaborative study within the Eurostars ...

Immune evasion continues to limit the effectiveness of cancer immunotherapies. Among emerging regulatory molecules, transfer RNA-derived small RNAs (tsRNAs of 13-48 nucleotides), generated through ...

IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy, for AML and Multiple Myeloma IND Cleared for FT819, the First iPSC-derived CAR T-cell Therapy, for Advanced B-cell Leukemias ...